Abstract:Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting liver disease that affects millions of people around the world. It is best identified with a hepatic fat build-up that ultimately leads to inflammation and damage. The classification and nomenclature of NAFLD have long been a controversial topic, until 2020 when a group of international experts recommended substituting NAFLD with MAFLD (metabolic dysfunction-associated FLD). MAFLD was then terminologically complemented in 2023 by altering it to MASLD, i.e., metabolic dysfunction-associated steatotic liver disease (MASLD). Both the MAFLD and the MASLD terminologies comprise the metabolic element of the disorder, as they offer diagnostic benchmarks that are embedded in the metabolic risk factors that underlie the disease. MASLD (as a multisystemic disease) provides a comprehensive definition that includes a larger population of patients who are at risk of liver morbidity and mortality, as well as adverse cardiovascular and diabetes outcomes. MASLD highlights metabolic risks in lean or normal weight individuals, a factor that has not been accentuated or discussed in previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, and exercise therapies have not been extensively studied in MAFLD and MASLD. Nutrition plays a vital role in managing both conditions, where centralizing on a diet rich in whole vegetables, fruits, foods, healthy fats, lean proteins, and specific nutrients (e.g., omega-3 fatty acids and fibers) can improve insulin resistance and reduce inflammation. Thus, it is essential to understand the role of nutrition in managing these conditions and to work with patients to develop an individualized plan for optimal health. This review discusses prevention strategies for NAFLD/MAFLD/MASLD management, with particular attention to nutrition and lifestyle correction.

Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence, Diagnosis, Treatment, and Outcomes: A Narrative Review

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study

S2018 Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: Higher Mortality and Complication Rates Compared to Higher BMI

Current status and future trends of the global burden of MASLD

Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Role of the Gut Microbiome in Metabolic dysfunction-Associated Steatotic Liver Disease

A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease

The Role of Microbiota-Related Co-Metabolites in MASLD Progression: A Narrative Review

The Global Epidemic of Metabolic Fatty Liver Disease

Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions

Manifestation and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Predominately African American Population at a Multi-Specialty Healthcare Organization

Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease

What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications